1887

Abstract

Strategies to induce potent and broad antibody responses against the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Env) at both systemic and mucosal sites represent a central goal for HIV-1 vaccine development. Here, we show that the non-toxic CTA1-DD adjuvant promoted mucosal and systemic humoral and cell-mediated immune responses following intranasal (i.n.) immunizations with trimeric or monomeric forms of HIV-1 Env in mice and in non-human primates. Env-specific IgG subclasses in the serum of immunized mice reflected a balanced Th1/Th2 type of response. Strikingly, i.n. immunizations with Env and the CTA1-DD adjuvant induced substantial levels of mucosal anti-Env IgA in bronchial alveolar lavage and also detectable levels in vaginal secretions. By contrast, parenteral immunizations of Env formulated in Ribi did not stimulate mucosal IgA responses, while the two adjuvants induced a similar distribution of Env-specific IgG-subclasses in serum. A single parenteral boost with Env in Ribi adjuvant into mice previously primed i.n. with Env and CTA1-DD, augmented the serum anti-Env IgG levels to similar magnitudes as those observed after three intraperitoneal immunizations with Env in Ribi. The augmenting potency of CTA1-DD was similar to that of LTK63 or CpG oligodeoxynucleotides (ODN). However, in contrast to CpG ODN, the effect of CTA1-DD and LTK63 appeared to be independent of MyD88 and toll-like receptor signalling. This is the first demonstration that CTA1-DD augments specific immune responses also in non-human primates, suggesting that this adjuvant could be explored further as a clinically safe mucosal vaccine adjuvant for humoral and cell-mediated immunity against HIV-1 Env.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.2008/005470-0
2008-12-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/12/2954.html?itemId=/content/journal/jgv/10.1099/vir.0.2008/005470-0&mimeType=html&fmt=ahah

References

  1. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K. & Akira, S. ( 1998; ). Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143–150.[CrossRef]
    [Google Scholar]
  2. Agren, L. C., Ekman, L., Lowenadler, B. & Lycke, N. Y. ( 1997; ). Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 158, 3936–3946.
    [Google Scholar]
  3. Akhiani, A. A., Pappo, J., Kabok, Z., Schon, K., Gao, W., Franzen, L. E. & Lycke, N. ( 2002; ). Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 169, 6977–6984.[CrossRef]
    [Google Scholar]
  4. Akhiani, A. A., Stensson, A., Schon, K. & Lycke, N. ( 2006; ). The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 63, 97–105.[CrossRef]
    [Google Scholar]
  5. Albrecht, H. ( 2003; ). Making sense of AIDSVAX. AIDS Clin Care 15, 42
    [Google Scholar]
  6. Andersen, C. S., Dietrich, J., Agger, E. M., Lycke, N. Y., Lovgren, K. & Andersen, P. ( 2007; ). The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun 75, 408–416.[CrossRef]
    [Google Scholar]
  7. Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D. & Persing, D. ( 2004; ). Taking a Toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 4, 1129–1138.[CrossRef]
    [Google Scholar]
  8. Barnett, S. W., Lu, S., Srivastava, I., Cherpelis, S., Gettie, A., Blanchard, J., Wang, S., Mboudjeka, I., Leung, L. & other authors ( 2001; ). The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75, 5526–5540.[CrossRef]
    [Google Scholar]
  9. Barnett, S. W., Srivastava, I. K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A. D., Ferrai, M. G., Weiss, D. E., Letvin, N. L. & other authors ( 2008; ). Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22, 339–348.[CrossRef]
    [Google Scholar]
  10. Barton, G. M. & Medzhitov, R. ( 2002; ). Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 14, 380–383.[CrossRef]
    [Google Scholar]
  11. Bergmeier, L. A. & Lehner, T. ( 2006; ). Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 19, 21–28.[CrossRef]
    [Google Scholar]
  12. Beutler, B. ( 2007; ). Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev 220, 113–128.[CrossRef]
    [Google Scholar]
  13. Binley, J. M., Sanders, R. W., Clas, B., Schuelke, N., Master, A., Guo, Y., Kajumo, F., Anselma, D. J., Maddon, P. J. & other authors ( 2000; ). A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74, 627–643.[CrossRef]
    [Google Scholar]
  14. Burton, D. R., Desrosiers, R. C., Doms, R. W., Koff, W. C., Kwong, P. D., Moore, J. P., Nabel, G. J., Sodroski, J., Wilson, I. A. & Wyatt, R. T. ( 2004; ). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5, 233–236.[CrossRef]
    [Google Scholar]
  15. Burton, D. R., Stanfield, R. L. & Wilson, I. A. ( 2005; ). Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 102, 14943–14948.[CrossRef]
    [Google Scholar]
  16. Choi, A. H., McNeal, M. M., Flint, J. A., Basu, M., Lycke, N. Y., Clements, J. D., Bean, J. A., Davis, H. L., McCluskie, M. J. & other authors ( 2002; ). The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 20, 1733–1740.[CrossRef]
    [Google Scholar]
  17. De Filette, M., Ramne, A., Birkett, A., Lycke, N., Lowenadler, B., Min Jou, W., Saelens, X. & Fiers, W. ( 2006; ). The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24, 544–551.[CrossRef]
    [Google Scholar]
  18. Derby, N. R., Kraft, Z., Kan, E., Crooks, E. T., Barnett, S. W., Srivastava, I. K., Binley, J. M. & Stamatatos, L. ( 2006; ). Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80, 8745–8762.[CrossRef]
    [Google Scholar]
  19. Dickinson, B. L. & Clements, J. D. ( 1995; ). Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63, 1617–1623.
    [Google Scholar]
  20. Eliasson, D. G., Bakkouri, K. E., Schon, K., Ramne, A., Festjens, E., Lowenadler, B., Fiers, W., Saelens, X. & Lycke, N. ( 2008; ). CTA1–M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26, 1243–1252.[CrossRef]
    [Google Scholar]
  21. Eriksson, A. M., Schon, K. M. & Lycke, N. Y. ( 2004; ). The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173, 3310–3319.[CrossRef]
    [Google Scholar]
  22. Forsell, M. N., McInerney, G. M., Dosenovic, P., Hidmark, A. S., Eriksson, C., Liljestrom, P., Grundner, C. & Karlsson Hedestam, G. B. ( 2007; ). Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector. J Gen Virol 88, 2774–2779.[CrossRef]
    [Google Scholar]
  23. Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B. & Nemazee, D. ( 2006; ). Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936–1938.[CrossRef]
    [Google Scholar]
  24. Girard, M. P., Bansal, G. P., Pedroza-Martins, L., Dodet, B., Mehra, V., Schito, M., Mathieson, B., Delfraissy, J. F. & Bradac, J. ( 2008; ). Mucosal immunity and HIV/AIDS vaccines Report of an International Workshop, 28–30 October 2007. Vaccine 26, 3969–3977.[CrossRef]
    [Google Scholar]
  25. Grdic, D., Ekman, L., Schon, K., Lindgren, K., Mattsson, J., Magnusson, K. E., Ricciardi-Castagnoli, P. & Lycke, N. ( 2005; ). Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J Immunol 175, 5192–5202.[CrossRef]
    [Google Scholar]
  26. Grundner, C., Pancera, M., Kang, J. M., Koch, M., Sodroski, J. & Wyatt, R. ( 2004; ). Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 330, 233–248.[CrossRef]
    [Google Scholar]
  27. Gupta, K. & Klasse, P. J. ( 2006; ). How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med 3, e79 [CrossRef]
    [Google Scholar]
  28. Guy, B. ( 2007; ). The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5, 505–517.[CrossRef]
    [Google Scholar]
  29. Haase, A. T. ( 2005; ). Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5, 783–792.[CrossRef]
    [Google Scholar]
  30. Harris, G., KuoLee, R. & Chen, W. ( 2006; ). Role of Toll-like receptors in health and diseases of gastrointestinal tract. World J Gastroenterol 12, 2149–2160.
    [Google Scholar]
  31. Haynes, B. F. & Shattock, R. J. ( 2008; ). Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol 122, 3–9.[CrossRef]
    [Google Scholar]
  32. Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. ( 2003; ). The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170, 3059–3064.[CrossRef]
    [Google Scholar]
  33. Hladik, F. & McElrath, M. J. ( 2008; ). Setting the stage: host invasion by HIV. Nat Rev Immunol 8, 447–457.[CrossRef]
    [Google Scholar]
  34. Hol, W. G. J., Sixma, T. K. & Merritt, E. A. ( 1995; ). Structure and function of E. coli heat-labile enterotoxin and cholera toxin B pentamer. In Natural Toxins: Bacterial Toxins and Virulence Factors in Disease, pp. 185–223. Edited by J. Moss, M. Vaughan, B. Iglewski & A. T. Tu. New York: Marcel Dekker, Inc.
  35. Karlsson Hedestam, G. B., Fouchier, R. A., Phogat, S., Burton, D. R., Sodroski, J. & Wyatt, R. T. ( 2008; ). The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6, 143–155.[CrossRef]
    [Google Scholar]
  36. Kim, M., Qiao, Z. S., Montefiori, D. C., Haynes, B. F., Reinherz, E. L. & Liao, H. X. ( 2005; ). Comparison of HIV type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 21, 58–67.[CrossRef]
    [Google Scholar]
  37. Kozlowski, P. A. & Neutra, M. R. ( 2003; ). The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 3, 217–228.[CrossRef]
    [Google Scholar]
  38. Kwissa, M., Kasturi, S. P. & Pulendran, B. ( 2007; ). The science of adjuvants. Expert Rev Vaccines 6, 673–684.[CrossRef]
    [Google Scholar]
  39. Lavelle, E. C., Jarnicki, A., McNeela, E., Armstrong, M. E., Higgins, S. C., Leavy, O. & Mills, K. H. ( 2004; ). Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol 75, 756–763.
    [Google Scholar]
  40. Levine, M. M. & Sztein, M. B. ( 2004; ). Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5, 460–464.[CrossRef]
    [Google Scholar]
  41. Li, Y., Svehla, K., Mathy, N. L., Voss, G., Mascola, J. R. & Wyatt, R. ( 2006; ). Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80, 1414–1426.[CrossRef]
    [Google Scholar]
  42. Liang, S., Wang, M., Triantafilou, K., Triantafilou, M., Nawar, H. F., Russell, M. W., Connell, T. D. & Hajishengallis, G. ( 2007; ). The A subunit of type IIb enterotoxin (LT-IIb) suppresses the proinflammatory potential of the B subunit and its ability to recruit and interact with TLR2. J Immunol 178, 4811–4819.[CrossRef]
    [Google Scholar]
  43. Lycke, N. ( 2007; ). Mechanisms of Adjuvant Action. In Vaccine Adjuvants and Delivery Systems, pp. 53–79. Edited by M. Singh. Hoboken, NJ: John Wiley & Sons.
  44. Maher, D., Wu, X., Schacker, T., Horbul, J. & Southern, P. ( 2005; ). HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A 102, 11504–11509.[CrossRef]
    [Google Scholar]
  45. Marks, E., Verolin, M., Stensson, A. & Lycke, N. ( 2007; ). Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection. Infect Immun 75, 4638–4647.[CrossRef]
    [Google Scholar]
  46. Mascola, J. R. ( 2003; ). Defining the protective antibody response for HIV-1. Curr Mol Med 3, 209–216.[CrossRef]
    [Google Scholar]
  47. Mazanec, M. B., Kaetzel, C. S., Lamm, M. E., Fletcher, D. & Nedrud, J. G. ( 1992; ). Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 89, 6901–6905.[CrossRef]
    [Google Scholar]
  48. Mazzoli, S., Trabattoni, D., Lo Caputo, S., Piconi, S., Ble, C., Meacci, F., Ruzzante, S., Salvi, A., Semplici, F. & other authors ( 1997; ). HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3, 1250–1257.[CrossRef]
    [Google Scholar]
  49. McGettrick, A. F. & O'Neill, L. A. ( 2007; ). Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 139, 185–193.[CrossRef]
    [Google Scholar]
  50. McNeal, M. M., Basu, M., Bean, J. A., Clements, J. D., Lycke, N. Y., Ramne, A., Lowenadler, B., Choi, A. H. & Ward, R. L. ( 2007; ). Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine 25, 6224–6231.[CrossRef]
    [Google Scholar]
  51. Mestecky, J., Moldoveanu, Z. & Russell, M. W. ( 2005; ). Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 53, 208–214.[CrossRef]
    [Google Scholar]
  52. Montefiori, D., Sattentau, Q., Flores, J., Esparza, J. & Mascola, J. ( 2007; ). Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4, e348 [CrossRef]
    [Google Scholar]
  53. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C. & Steffen, R. ( 2004; ). Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350, 896–903.[CrossRef]
    [Google Scholar]
  54. Neutra, M. R. & Kozlowski, P. A. ( 2006; ). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6, 148–158.[CrossRef]
    [Google Scholar]
  55. Parren, P. W., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P. & Burton, D. R. ( 2001; ). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75, 8340–8347.[CrossRef]
    [Google Scholar]
  56. Pasare, C. & Medzhitov, R. ( 2005; ). Control of B-cell responses by Toll-like receptors. Nature 438, 364–368.[CrossRef]
    [Google Scholar]
  57. Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W. & Choopanya, K. ( 2006; ). Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194, 1661–1671.[CrossRef]
    [Google Scholar]
  58. Sanders, R. W., Vesanen, M., Schuelke, N., Master, A., Schiffner, L., Kalyanaraman, R., Paluch, M., Berkhout, B., Maddon, P. J. & other authors ( 2002; ). Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76, 8875–8889.[CrossRef]
    [Google Scholar]
  59. Shattock, R. J., Haynes, B. F., Pulendran, B., Flores, J. & Esparza, J. ( 2008; ). Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5, e81 [CrossRef]
    [Google Scholar]
  60. Simmons, C. P., Mastroeni, P., Fowler, R., Ghaem-maghami, M., Lycke, N., Pizza, M., Rappuoli, R. & Dougan, G. ( 1999; ). MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 163, 6502–6510.
    [Google Scholar]
  61. Sin, J. I., Kim, J. J., Boyer, J. D., Ciccarelli, R. B., Higgins, T. J. & Weiner, D. B. ( 1999; ). In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 73, 501–509.
    [Google Scholar]
  62. Srivastava, I. K., VanDorsten, K., Vojtech, L., Barnett, S. W. & Stamatatos, L. ( 2003; ). Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 77, 2310–2320.[CrossRef]
    [Google Scholar]
  63. Stephenson, I., Zambon, M. C., Rudin, A., Colegate, A., Podda, A., Bugarini, R., Del Giudice, G., Minutello, A., Bonnington, S. & other authors ( 2006; ). Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80, 4962–4970.[CrossRef]
    [Google Scholar]
  64. Tritto, E., Muzzi, A., Pesce, I., Monaci, E., Nuti, S., Galli, G., Wack, A., Rappuoli, R., Hussell, T. & De Gregorio, E. ( 2007; ). The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 179, 5346–5357.[CrossRef]
    [Google Scholar]
  65. Underhill, D. M. & Ozinsky, A. ( 2002; ). Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14, 103–110.[CrossRef]
    [Google Scholar]
  66. Vajdy, M., Singh, M., Kazzaz, J., Soenawan, E., Ugozzoli, M., Zhou, F., Srivastava, I., Bin, Q., Barnett, S. & other authors ( 2004; ). Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 20, 1269–1281.[CrossRef]
    [Google Scholar]
  67. Veazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J. & other authors ( 2003; ). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9, 343–346.[CrossRef]
    [Google Scholar]
  68. Vogel, F. R. ( 1995; ). Immunologic adjuvants for modern vaccine formulations. Ann N Y Acad Sci 754, 153–160.[CrossRef]
    [Google Scholar]
  69. Wicker, S., Rabenau, H. F., Gottschalk, R., Doerr, H. W. & Allwinn, R. ( 2007; ). Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol 196, 145–150.[CrossRef]
    [Google Scholar]
  70. Xu, R., Srivastava, I. K., Greer, C. E., Zarkikh, I., Kraft, Z., Kuller, L., Polo, J. M., Barnett, S. W. & Stamatatos, L. ( 2006a; ). Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22, 1022–1030.[CrossRef]
    [Google Scholar]
  71. Xu, R., Srivastava, I. K., Kuller, L., Zarkikh, I., Kraft, Z., Fagrouch, Z., Letvin, N. L., Heeney, J. L., Barnett, S. W. & Stamatatos, L. ( 2006b; ). Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349, 276–289.[CrossRef]
    [Google Scholar]
  72. Yang, X., Florin, L., Farzan, M., Kolchinsky, P., Kwong, P. D., Sodroski, J. & Wyatt, R. ( 2000; ). Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 74, 4746–4754.[CrossRef]
    [Google Scholar]
  73. Yang, X., Wyatt, R. & Sodroski, J. ( 2001; ). Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75, 1165–1171.[CrossRef]
    [Google Scholar]
  74. Yang, X., Lee, J., Mahony, E. M., Kwong, P. D., Wyatt, R. & Sodroski, J. ( 2002; ). Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76, 4634–4642.[CrossRef]
    [Google Scholar]
  75. Zignol, M., Peracchi, M., Tridello, G., Pillon, M., Fregonese, F., D'Elia, R., Zanesco, L. & Cesaro, S. ( 2004; ). Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 101, 635–641.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.2008/005470-0
Loading
/content/journal/jgv/10.1099/vir.0.2008/005470-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error